Search
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14619ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14620ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (UV,formaldehyde inactivated)
go.drugbank.com/drugs/DB14699ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Synonyms: INFLUENZA A VIRUS A/URUGUAY/716/2007(H3N2) HEMAGGLUTININ ANTIGEN (UV,FORMALDEHYDE INACTIVATED)Influenza A virus A/Indiana/08/2018 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15506ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Kansas/14/2017 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB15514ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Brisbane/02/2018 (H1N1) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15517ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Kansas/14/2017 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15518ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/North carolina/04/2016 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15562ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15620ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15621ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.